Keywords: USA, FDA, AstraZeneca, Brilinta, Savient, Krystexxa, Sale of company
US FDA extends approval time for AstraZeneca’s Brilinta; OKs Savient’s Krystexxa, which could lead to sale of the firm
Article | 15 September 2010
The US Food and Drug Administration has extended the time to complete its review of the New Drug Application for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
